Pharmaceutical composition for preventing in-stent restenosis

A composition and restenosis technology, which is applied in the direction of drug combination, surgical drug, pharmaceutical formula, etc., can solve the problem of high preoperative complication rate, achieve the effect of improving motor dysfunction, preventing recurrence, and preventing in-stent restenosis

Pending Publication Date: 2021-09-17
SAPPORO MEDICAL UNIVERSITY +1
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The off-label application of DES relative to intracranial artery disease has also been tried, but due to technical obstacles caused by the rigidity of the stent and neurotoxicity, the preoperative complication rate is high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for preventing in-stent restenosis
  • Pharmaceutical composition for preventing in-stent restenosis
  • Pharmaceutical composition for preventing in-stent restenosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0090] 1. Materials and methods

[0091] (1) Preparation of human mesenchymal stem cells

[0092] Human MSCs were prepared according to previous reports. That is, MSC (P2) was purchased from Lonza Corporation (Walkersville, MD), diluted with Dulbecco's modified eagle medium (Dulbecco's modified eagle medium), added 10% FBS (Life Technologies company), 2mM L-glutamine ( Sigma-Aldrich Company), 100U / ml penicillin-streptomycin (Sigma-Aldrich Company), inoculated into 150mm tissue culture dish (IWAKI Company), in 5% CO 2 Incubate for several days at 37°C in a humidified atmosphere. When the cells reached confluence, trypsin-EDTA solution (Mediatech Inc.) was used to detach the adherent cells, and 1 × 10 4 cells / ml for subculture. Thus, MSCs were proliferated to 1×10 with a short culture time (passage: 4 times) 8 cell. The proliferated MSCs were isolated, and on the day of stent insertion, the preservation solution [RPMI (Life Technologies Company) 8 ml, autologous serum 8 ml...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a pharmaceutical composition containing mesenchymal stem cells to be administered to a patient who has undergone stent implantation. Specifically, the present invention relates to the pharmaceutical composition which is a pharmaceutical composition for tissue repair / regeneration characterized by containing mesenchymal stem cells and being administered to a patient who has undergone stent implantation; and to the prevention of in-stent neointimal hyperplasia or in-stent restenosis by the pharmaceutical composition.

Description

technical field [0001] related application [0002] This specification includes the contents described in the specification of Japanese Patent Application No. 2019-020707 (filed on February 7, 2019), which is the basis of the priority of this application. technical field [0003] The present invention relates to a pharmaceutical composition comprising mesenchymal stem cells administered to a patient undergoing stent placement. The pharmaceutical composition of the present invention is administered to a patient receiving a stent to promote tissue repair and regeneration of an affected part and prevent in-stent restenosis. Background technique [0004] Carotid Artery Stenting (CAS) or Percutaneous Transluminal Angioplasty and Stenting (PTAS) performed in the treatment of carotid artery or intracranial atherosclerosis. Restenosis is a serious complication leading to recurrence of stroke (cerebral infarction). Although a low risk of ipsilateral infarct recurrence after CAS ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/28A61P9/10A61P9/14A61P41/00A61P43/00A61L31/00A61L31/16
CPCA61P41/00A61P9/14A61P9/10A61K35/28A61L27/3834A61L27/54A61L2300/64A61L27/38A61L31/16A61P43/00
Inventor 本望修佐佐木祐典佐佐木优子冈真一中崎公仁前泽理惠
Owner SAPPORO MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap